Cargando…

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation

Purpose: This study evaluated the clinical efficacy and safety of bromfenac 0.09%, sodium hyaluronate 0.4% (SH) combination therapy, versus placebo and SH in a clinical model of pterygium I–III. Methods: A total of 166 eyes (99 patients) with pterygium grade I–III were randomized to bromfenac 0.09%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chávez-Mondragón, Eduardo, Palacio, Claudia, Soto-Gómez, Abraham, Villanueva-Nájera, Miguel, De Wit-Carter, Guillermo, Suárez-Velasco, Ruben, Baiza-Duran, Leopoldo, Olvera-Montaño, Oscar, Muñoz-Villegas, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507105/ https://www.ncbi.nlm.nih.gov/pubmed/31118556 http://dx.doi.org/10.2147/OPTH.S203648

Ejemplares similares

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis
por: Saade, Joanna S., et al.
Publicado: (2021)

Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population
por: Palacio, Claudia, et al.
Publicado: (2016)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site
por: Cable, Melissa
Publicado: (2012)

KMg(0.09)Fe(1.91)(PO(4))(2)
por: Yatskin, Michael M., et al.
Publicado: (2012)

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana, Claudia, et al.
Publicado: (2020)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Erbium-doped (Pb(0.9)-Er(0.01)-Zr(0.09)) and (Pb(0.9)-Er(0.01)-Zr(0.045)-Ti(0.045)) nano-crystalline films and nano-rods ceramic synthesis by sol–gel technique for energy-storage application
por: Ibrahim, F. A., et al.
Publicado: (2023)

Crystal structure of the cubic double-perovskite Sr(2)Cr(0.84)Ni(0.09)Os(1.07)O(6)
por: Chen, Jie, et al.
Publicado: (2022)

Flexible Lead-Free Piezoelectric Ba(0.94)Sr(0.06)Sn(0.09)Ti(0.91)O(3)/PDMS Composite for Self-Powered Human Motion Monitoring
por: Deng, Lin, et al.
Publicado: (2023)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021)

Ultra Uniform Pb(0.865)La(0.09)(Zr(0.65)Ti(0.35))O(3) Thin Films with Tunable Optical Properties Fabricated via Pulsed Laser Deposition
por: Jiang, Shenglin, et al.
Publicado: (2018)

Epitaxial Growth of Sc(0.09)Al(0.91)N and Sc(0.18)Al(0.82)N Thin Films on Sapphire Substrates by Magnetron Sputtering for Surface Acoustic Waves Applications
por: Bartoli, Florian, et al.
Publicado: (2020)

Coercivity and Magnetic Anisotropy of (Fe(0.76)Si(0.09)B(0.10)P(0.05))(97.5)Nb(2.0)Cu(0.5) Amorphous and Nanocrystalline Alloy Produced by Gas Atomization Process
por: Alvarez, Kenny L., et al.
Publicado: (2020)

Enhancing the Electrochemical Performance of Ni-Rich LiNi(0.88)Co(0.09)Al(0.03)O(2) Cathodes through Tungsten-Doping for Lithium-Ion Batteries
por: Zhang, Rui, et al.
Publicado: (2022)

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery
por: Jung, Ji Won, et al.
Publicado: (2015)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John A, et al.
Publicado: (2021)

Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate
por: Mercado-Sesma, Arieh, et al.
Publicado: (2017)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
por: Baiza-Durán, Leopoldo M., et al.
Publicado: (2023)

Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
por: Song, Seok Hyeon, et al.
Publicado: (2020)

Switching Characteristics and High-Temperature Dielectric Relaxation Behaviours of Pb(Zn(1/3)Nb(2/3))(0.91)Ti(0.09)O(3) Single Crystal
por: Zhu, Zhi, et al.
Publicado: (2017)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Structure and Spectral Luminescence Properties of (ZrO(2))(0.909)(Y(2)O(3))(0.09)(Eu(2)O(3))(0.001) Ceramics Synthesized by Uniaxial Compaction and Slip Casting
por: Borik, Mikhail, et al.
Publicado: (2022)

Study of diffuse phase transition and relaxor ferroelectric behavior of Ba(0.97)Bi(0.02)Ti(0.9)Zr(0.05)Nb(0.04)O(3) ceramic
por: Raddaoui, Z., et al.
Publicado: (2019)

Topical Bromfenac Sodium in Femtosecond Laser-Assisted Cataract Surgery
por: Aguilar Sierra, María Camila, et al.
Publicado: (2020)

Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial
por: Pérez-Balbuena, Ana L., et al.
Publicado: (2016)

The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan, George A, et al.
Publicado: (2014)

Synthesis of a fine LiNi(0.88)Co(0.09)Al(0.03)O(2) cathode material for lithium-ion batteries via a solvothermal route and its improved high-temperature cyclic performance
por: Cao, Guolin, et al.
Publicado: (2020)

Effect of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (Voluven®) on complications after subarachnoid hemorrhage: a retrospective analysis
por: Khan, Shariq A, et al.
Publicado: (2013)

Usefulness of Ready-to-Use 0.4% Sodium Hyaluronate (Endo-Ease) in the Endoscopic Resection of Gastrointestinal Neoplasms
por: Kim, Eun Ran, et al.
Publicado: (2015)

Structure properties and dielectric relaxation of Ca(0.1)Na(0.9)Ti(0.1)Nb(0.9)O(3) ceramic
por: Ghoudi, Hanen, et al.
Publicado: (2019)

Cosmology, Gravity, and the WMAP ratio 0.73:0.23:0.04
por: Smith, F D T
Publicado: (2004)

Enhanced Tunability Achieving at Low Permittivity and Electric Field in (Ba(0.91)Ca(0.09))(Sn(x)Zr(0.2)(−)(x)Ti(0.8))O(3)-2 mol% CuO-1 mol% Li(2)CO(3) Ceramics
por: Wang, Bo, et al.
Publicado: (2023)

Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

A Supernova Search At Z = 0.2 - 0.4
por: Hardin, D
Publicado: (2000)

Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study
por: Guidet, Bertrand, et al.
Publicado: (2012)

Structural, Optical and Electrical Properties of Cu(0.6)Co(x)Zn(0.4−x)Fe(2)O(4) (x = 0.0, 0.1, 0.2, 0.3, 0.4) Soft Ferrites
por: Farooq, W. Aslam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d44ph6ldhh1l2ad3j18mim90au